Pharmaceutical unit-dose repackaging and supply chain solutions company Safecor Health, a Vesey Street Capital Partners (VSCP) portfolio company, announced on Monday that it has acquired the US unit-dose packaging business of pharmaceutical company Viatris Inc (NASDAQ:VTRS).
The business was previously called Unit Dose Laboratories (UDL). Established in 1980, it provides unit-dose generic medicines to institutional and long-term care facilities.
The acquisition is expected to be finalised in the first half of 2025, with no immediate action required by customers or partners at this time.
Safecor CEO Mark Saxon, said: "Adding the UDL team, the strong brand recognition, and their capabilities to the Safecor family will further our ongoing goal of providing world-class packaging and supply chain solutions to the manufacturers and health systems we serve. With this addition, we'll immediately increase the number of unit-dose commercial products we offer, and we plan to grow the offering with expanded manufacturer, health system, and wholesaler relationships."
CivicaScript to distribute biosimilar for chronic inflammatory conditions
Mallinckrodt and Endo complete merger
Zenara Pharma's Sertraline Hydrochloride Capsules generic receives US FDA approval
EQT agrees to acquire majority stake in Adalvo
Mallinckrodt receives Irish High Court ruling to combine with Endo Inc
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CivicaScript introduces low-cost multiple sclerosis treatment
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment
Avera joins Civica to help maintain drug supplies
Apotex launches generic version of Tasigna in US market
CivicaScript launches droxidopa for symptomatic neurogenic orthostatic hypotension
Padagis' Naloxone HCl Nasal Spray 4 mg obtains extended shelf-life of 36 months
ANI Pharmaceuticals announces US launch of Nitazoxanide Tablets